Research Analysts Offer Predictions for DMAC FY2025 Earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.72) per share for the year, up from their previous forecast of ($0.73). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($0.45) EPS.

DiaMedica Therapeutics Price Performance

DMAC opened at $4.20 on Monday. The firm has a market capitalization of $180.11 million, a price-to-earnings ratio of -7.50 and a beta of 1.29. The company's 50 day simple moving average is $4.13 and its two-hundred day simple moving average is $5.00. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). During the same quarter in the previous year, the firm posted ($0.14) EPS.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DMAC. Balyasny Asset Management L.P. acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at $79,000. Y Intercept Hong Kong Ltd purchased a new position in DiaMedica Therapeutics during the 4th quarter valued at about $81,000. Raymond James Financial Inc. acquired a new position in DiaMedica Therapeutics in the 4th quarter valued at about $83,000. Bank of Montreal Can purchased a new stake in DiaMedica Therapeutics during the fourth quarter worth about $84,000. Finally, Cornerstone Wealth Management LLC purchased a new stake in DiaMedica Therapeutics during the first quarter worth about $62,000. Institutional investors and hedge funds own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.